SCHEMBL12888467

SCHEMBL12888467

Fc1ccc(-c2nc(Cl)c(F)c(Cl)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHPS P49366 1/20 0.45
▸ KMT2A Q03164 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ PTGS2 P35354 1/20 0.40
▸ TXN P10599 1/20 0.40
▸ NPC1 O15118 6/20 0.39
▸ RAB9A P51151 6/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ TP53 P04637 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ DPP4 P27487 2/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ POLB P06746 1/20 0.36
▸ ABCG2 Q9UNQ0 1/20 0.36
▸ AHR P35869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12888470 0.86 NPC1 (0.54) DHPSKMT2AMEN1HTTNPC1
SCHEMBL12888460 0.83 PTGS2 (0.51) DHPSKMT2AMEN1HTTPTGS2
SCHEMBL19995446 0.80 KMT2A (0.46) KMT2AMEN1HTTNPC1RAB9A
SCHEMBL6017000 0.80 RAB9A (0.47) KMT2AMEN1HTTNPC1RAB9A
SCHEMBL6016966 0.79 TXN (0.55) DHPSKMT2AMEN1HTTTXN
SCHEMBL6017041 0.79 TXN (0.50) DHPSKMT2AMEN1HTTTXN
SCHEMBL18096156 0.78 DHPS (0.61) DHPSPTGS2NPC1RAB9A
SCHEMBL23733877 0.78 BCL2L1 (0.48) KMT2AMEN1HTTTXNNPC1
SCHEMBL17269527 0.78 BCL2L1 (0.48) KMT2AMEN1HTTTXNNPC1
SCHEMBL3450860 0.77 LMNA (0.47) DHPSKMT2AMEN1PTGS2TXN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575338-B2 Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-11-05 — — US disclosed
US-8575338-B2 Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-11-05 — — US disclosed
US-20110034435-A1 PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 — — US disclosed
US-20110034435-A1 PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 — — US disclosed
WO-2009125870-A1 PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS. MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034435-A1 PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS KCNJ2, KCNJ1, KCNJ11 DHPS 1620/4885KMT2A 1719/4885MEN1 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback